- Alzprotect currently has the world’s most advanced clinical development program for the treatment of PSP.
- Progressive Supranuclear Palsy (PSP) affects over 25,000 US citizens each year. The American market therefore represents the main world market for the treatment of PSP.
- Phase 2a for the treatment of PSP went well and was completed on July 17, 2022.
Dedicated team
Pierre Le Sourd
Xerys Expert
Jacqueline Lecouturier
Xerys Expert
Aïda Thiam
Business manager and committee member
Recent Posts
Alzprotect Awarded a Grant from The Michael J. Fox Foundation to Advance Small Molecule Parkinson’s Disease Program
Lille, France – June 1st 2022 – Alzprotect, a French biopharmaceutical company involved in the development of new therapeutic solutions in the neurodegenerative diseases ...
Read more...
Read more...
Alzprotect strengthens its Intellectual Property Portfolio for its First-in-Class Clinical Stage Drug Ezeprogind
Lille (France), November 23rd, 2020 ALZPROTECT, a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases announces today that the United ...
Read more...
Read more...
AlzProtect develops drugs for the treatment of neurodegenerative diseases, including Alzheimer’s disease -2
With an ageing population in industrialised countries, the number of people affected by Alzheimer's disease is increasing dramatically. According to the ...
Read more...
Read more...
XERYS FRANCE
73 boulevard haussmann
75008 Paris - France
+33 (0)1 82 52 12 25